1. Home
  2. GHG vs KZIA Comparison

GHG vs KZIA Comparison

Compare GHG & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GHG

GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

N/A

Current Price

$1.18

Market Cap

119.1M

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$13.50

Market Cap

100.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHG
KZIA
Founded
2004
1994
Country
China
Australia
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.1M
100.8M
IPO Year
2017
2002

Fundamental Metrics

Financial Performance
Metric
GHG
KZIA
Price
$1.18
$13.50
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.50
AVG Volume (30 Days)
8.5K
169.2K
Earning Date
04-29-2026
06-04-2026
Dividend Yield
4.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.02
N/A
Revenue Next Year
$8.26
N/A
P/E Ratio
$5.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$4.86
52 Week High
$2.78
$17.40

Technical Indicators

Market Signals
Indicator
GHG
KZIA
Relative Strength Index (RSI) 57.33 52.39
Support Level $1.16 $5.44
Resistance Level $1.29 $14.75
Average True Range (ATR) 0.03 1.04
MACD 0.01 -0.15
Stochastic Oscillator 99.37 46.92

Price Performance

Historical Comparison
GHG
KZIA

About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The Group reports its financial results in two operating segments: Hotel Business, which consists of leased-and-operated hotels and franchised-and-managed hotels operating under the hotel related brand, and Restaurant Business, which consists of leased-and-operated restaurants and franchised-and-managed restaurants operating under the brands of Da Niang and Bellagio. It derives maximum revenue from Hotel Business segment. It operates solely in China and generates all its revenue from China itself.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: